Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives
- DOI
- 10.2147/ceor.s626752
- Published
- 2026-07
- Container
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2147/ceor.s626752,
title = {Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives},
author = {Jennifer E Vaughn and Nadine Zawadzki and Shurui Zhang and Paul Pinkston and David Wei and Jason Shafrin},
year = {2026},
journal = {ClinicoEconomics and Outcomes Research},
doi = {10.2147/ceor.s626752},
url = {https://doi.org/10.2147/ceor.s626752}
}RIS
TY - JOUR TI - Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives AU - Jennifer E Vaughn AU - Nadine Zawadzki AU - Shurui Zhang AU - Paul Pinkston AU - David Wei AU - Jason Shafrin PY - 2026 JO - ClinicoEconomics and Outcomes Research DO - 10.2147/ceor.s626752 UR - https://doi.org/10.2147/ceor.s626752 ER -
APA
Vaughn, J. E., Zawadzki, N., Zhang, S., Pinkston, P., Wei, D., & Shafrin, J. (2026). Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s626752
Source records
- crossref · retrieved 2026-09-26T12:41:50.268Z